Cadila Healthcare has received its board’s approval to raise funds by issue of Equity Shares/convertible Bonds/Debentures through Qualified Institutional Placement (QIP)/GDR/ ADR, for an aggregate amount up to Rs 10,000 crore. The meeting of the Board of Directors of the company held on May 25, 2018, approved the same.
The company has also received approval to issue Secured/ Unsecured Redeemable Non-Convertible Debentures/ Foreign Currency Bonds on private Placement Basis for an amount up to Rs 3,500 crore in the FY 2017-2018. The Board also approved the issue of Foreign Currency Bond/Foreign Currency Convertible Bonds for an amount up to Rs 5,000 crore.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
